RTKs can activate Ras, a protein that is tethered to the plasma membrane, by causing it to bind GTP. Once activated, Ras can do a variety of things. In this example, it activates an enzymatic cascade ...
Histone deacetylase (HDAC) inhibitors are expected to be effective for refractory cancer because their mechanism of action differs from that of conventional antineoplastic agents. In this study, we ...
Patients with NSCLC who underwent RT for spine metastasis and tumor genetic profiling were ascertained. Associations between driver gene mutations incidence of local failure were analyzed, followed by ...
The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...
Concurrent Inhibition of The RAS Pathway and Autophagy As a Treatment Approach for Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that inhibition ...
Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, ...
Mitogen-activated protein kinase (MAPK) networks are essential for the transmission of extracellular signals into appropriate intracellular responses. Prototypical MAPK activation implements a ...
SOUTH SAN FRANCISCO - BridgeBio Oncology Therapeutics (NASDAQ:BBOT) announced Wednesday preliminary safety and efficacy data from three clinical-stage programs targeting RAS-pathway malignancies. The ...
Daraxonrasib improved survival in metastatic pancreatic cancer in Phase III, signaling meaningful progress for therapies targeting RAS‑driven disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results